Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Unmet needs of immunotherapy for bladder cancer

Prantik Das • 18 Feb 2022
GU Cancers 2022
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma

Prantik Das, MBBS, MRCP, FRCR, PG Dip, UHDB NHS Foundation Trust, Derby, UK and University of Nottingham, Nottingham, UK, discusses some of the challenges of immunotherapy in clinical practice for bladder cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Prantik Das

Unmet clinical needs in bladder cancer care in the UK
1:12
Unmet clinical needs in bladder cancer care in the UK
Prantik Das • 18 Feb 2022
Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC
2:12
Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC
Prantik Das • 18 Feb 2022
Hypofractionated radiotherapy for the management of prostate cancer
2:28
Hypofractionated radiotherapy for the management of prostate cancer
Prantik Das • 8 Mar 2019
The benefits of using patient reported outcomes in prostate cancer
3:14
The benefits of using patient reported outcomes in prostate cancer
Prantik Das • 8 Mar 2019

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals